According to ProGenTech, the system will incorporate Innovative Biosensor’s proprietary Cellular Analysis and Notification of Antigen Risks and Yields technology, a cell-based approach for detecting various pathogens, into a modified version of ProGenTech’s Entura Lite platform with integrated optical detection capabilities. Innovative Biosensors will commercialize the developed product and financial terms of the deal were not disclosed.
Joe Hernandez, president and CEO of Innovative Biosensors, said: We believe that having more rapid, highly sensitive assays and fully integrated systems is of immense value to the clinical diagnostic market. The combinations of our two technologies will achieve this panacea. We look forward to working with ProGenTech in revolutionizing this very important market.
Trevor Hawkins, chairman and CEO of ProGenTech, said: This is a clear validation of the ProGenTech technology and will be yet another avenue for us to create value from our product portfolio and knowhow. In combination with the groundbreaking Innovative Biosensors technology, this new product will enable radical improvements in diagnosis and treatment.
Innovative Biosensors develops novel technologies for the rapid detection of pathogens in biodefense applications and human clinical diagnostics.
ProGenTech is a life science and molecular diagnostics company developing instrumentation for nucleic acid and protein purification and molecular diagnostic testing.